logo
What Works for Low Back Pain? Not Much, a New Study Says

What Works for Low Back Pain? Not Much, a New Study Says

New York Times18-03-2025

Acetaminophen. Acupuncture. Massage. Muscle relaxants. Cannabinoids. Opioids. The list of available treatments for low back pain goes on and on. But there's not good evidence that these treatments actually reduce the pain, according to a new study that summarized the results of hundreds of randomized trials.
Low back pain affects an estimated one in four American adults and is the leading contributor to disability globally. In most diagnosed cases, the pain is considered 'nonspecific,' meaning it doesn't have a clear cause. That's also partly what makes it so hard to treat.
In the study, published on Tuesday in the journal BMJ Evidence-Based Medicine, researchers reviewed 301 randomized trials that compared 56 noninvasive treatments for low back pain, like medications and exercise, with placebos. They used a statistical method to combine the results of those studies and draw conclusions, a process known as a meta-analysis.
The researchers found that only one treatment — the use of nonsteroidal anti-inflammatory drugs, or NSAIDs, like ibuprofen and aspirin — was effective at reducing short-term, or acute, low back pain. Five other treatments had good enough evidence to be considered effective at reducing chronic low back pain. These were exercise; spinal manipulation, like you might receive from a chiropractor; taping the lower back; antidepressants; and the application of a cream that creates a warming sensation. Even so, the benefit was small.
'The big takeaways from this paper are that low back pain is exceptionally difficult to treat,' said Steve Davidson, the associate director of the N.Y.U. Pain Research Center, who was not involved in the study. 'There are a few treatments that they found that were effective, but those that were effective are marginally clinically effective.'
There was good evidence, for example, that exercise can reduce chronic back pain. But it only reduced the intensity of pain by an average of 7.9 points on a 0-to-100 pain scale — less than what most doctors consider to be a clinically meaningful difference.
Say a patient rates his or her pain as 7 out of 10, said Dr. Prasad Shirvalkar, an associate professor of pain medicine at the University of California, San Francisco. 'If I tell you, 'What if I could get you to a 6.3 from that 7? Wouldn't that be great?'' he said. 'Not really. And that's the effect size.'
Dr. David Clark, a professor of anesthesia at Stanford Medicine and a pain physician at the Palo Alto V.A. Medical Center, said the findings aligned with his experience as a practitioner. 'Most of what we try does not work very well for patients,' he said.
Still, he and other experts said the study affirmed that some common therapies may provide moderate relief.
For example, Dr. Shirvalkar said, there are many different types of NSAIDs, and it's possible they are underused. 'People might try two or three of them and have side effects, but doctors don't try other ones,' he said.
And though the magnitude of the effect was small, doctors said they still believe that exercise is likely to help with back pain in the long term. Core exercises, like planks, help strengthen muscles that in turn support the spine, Dr. Shirvalkar said. And exercise has other benefits aside from lowering pain intensity, Dr. Clark said, like improving strength, mobility and mood and reducing the extent to which pain interferes with a task.
Aidan Cashin, the paper's first author and deputy director of the research group Center for Pain IMPACT at Neuroscience Research Australia, said the aim of the study was to identify which first-line treatments for low back pain had any specific effects beyond a placebo, which might merit further study and which may not be worth pursuing. There was good evidence, for example, that paracetamol (acetaminophen) does little to nothing for acute low back pain.
The study included a long list of treatments for which the evidence was 'inconclusive' because the number of participants studied was too small or there was a strong risk of bias in the research.
That doesn't necessarily mean those treatments are ineffective, experts said. One limitation of the type of analysis that Dr. Cashin conducted was that it aggregated data from different studies and different populations in order to emulate one large trial. But in the process, a strong signal from one study that a treatment worked could be diluted amid noise from other studies that may not have been designed as well, he said.
For example, the review found that the evidence for interventions like heat (such as from a heating pad), massage and acupressure was of low certainty, but those treatments did reduce the intensity of pain by around 20 points.
The evidence for something like heat might be inconclusive, doctors said, but they would still recommend that patients try it. 'It's cheap, it's accessible, it almost causes no harm,' Dr. Shirvalkar said.
Dr. Davidson said the treatments for which there was inconclusive evidence offered a starting point for more research.
'What that list shows is that we have things to work with in terms of looking at different ways to treat low back pain,' he said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Scientists investigate little-known side effect of next-gen power plants: 'So important'
Scientists investigate little-known side effect of next-gen power plants: 'So important'

Yahoo

time16 minutes ago

  • Yahoo

Scientists investigate little-known side effect of next-gen power plants: 'So important'

In a study from the University of California, Davis published in Nature Water, scientists explained how floating solar projects impact birds and other wildlife, as explained in a summary published on Since 71% of the Earth is covered by water, placing solar panels on bodies of water is becoming a popular way to increase affordable energy projects without displacing land use. However, few studies have been done about how solar panels on water, or floating photovoltaics, affect aquatic wildlife. According to the National Audubon Society, more than 33% of bird populations in the U.S. are at high or moderate conservation concern. "Habitat loss due to agricultural intensification and urbanization is arguably the biggest threat to birds, along with climate change," said Virginia Tech associate professor in the College of Natural Resources and Environment Ashley Dayer in a school press release. "That's why it's so important to understand how waterbirds are going to respond to floating solar and if there is the possibility for conservation concessions at new floating solar facilities," said Elliott Steele, a UC Davis Wild Energy Center postdoctoral scholar who co-authored the study, per the summary. "We want to advance clean energy while promoting healthy, functional environments," Steele continued. "Achieving this balance requires that we rigorously study and understand how wildlife responds to floating solar so we can ensure that negative impacts are avoided and potential ecological benefits are realized." In the study, UC Davis scientists investigated how floating photovoltaic projects could impact birds. They documented a wide diversity of birds and their interactions with floating solar panels, as well as human interactions with wildlife on solar panels, sometimes trying to deter them. "We immediately knew this was a very important interaction, especially given the precipitous decline in waterbird numbers globally," said UC Davis professor Rebecca R. Hernandez in the summary. "We leveraged our team's expertise in ecology and energy system science to identify risks and solution pathways such that waterbirds and floating PV can coexist." "While we're at this critical threshold of renewable energy development, we want to put more thought into the design that can benefit birds and other wildlife as we go forward," said UC Davis Ph.D. candidate Emma Forester, per The scientists concluded that more research needs to be done to further explore how waterbirds interact with floating solar panels, as well as the effects they have on each other. What's the biggest obstacle stopping your organization from using solar panels? They're too expensive Don't know where to start They're an eyesore We already use solar panels Click your choice to see results and speak your mind. According to the summary, the authors have continued studying this in the field, noticing "black-crowned night herons resting on a floating solar structure before dawn, double-breasted cormorants jockeying for a favorable site, black phoebes nesting under panels, and more." Solar panels can help decrease harmful planet-warming pollution from other energy sources, like coal and natural gas, which contribute to loss of habitat for waterbirds. However, solar panels do take up land. According to the National Renewable Energy Laboratory, it would take up to 0.8% of the entire area of the United States to meet our energy needs. With floating solar panels, scientists could create solar systems that don't destroy habitats. Incorporating solar panels onto bodies of water or in farm systems could have added benefits, including water retention and space savings. Fortunately, scientists have noticed positive interaction with water birds and floating solar panels so far. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

‘We're Just Becoming a Weapon of the State'
‘We're Just Becoming a Weapon of the State'

Atlantic

time31 minutes ago

  • Atlantic

‘We're Just Becoming a Weapon of the State'

Since winning President Donald Trump's nomination to serve as the director of the National Institutes of Health, Jay Bhattacharya—a health economist and prominent COVID contrarian who advocated for reopening society in the early months of the pandemic—has pledged himself to a culture of dissent. 'Dissent is the very essence of science,' Bhattacharya said at his confirmation hearing in March. 'I'll foster a culture where NIH leadership will actively encourage different perspectives and create an environment where scientists, including early-career scientists and scientists that disagree with me, can express disagreement, respectfully.' Two months into his tenure at the agency, hundreds of NIH officials are taking Bhattacharya at his word. More than 300 officials, from across all of the NIH's 27 institutes and centers, have signed and sent a letter to Bhattacharya that condemns the changes that have thrown the agency into chaos in recent months—and calls on their director to reverse some of the most damaging shifts. Since January, the agency has been forced by Trump officials to fire thousands of its workers and rescind or withhold funding from thousands of research projects. Tomorrow, Bhattacharya is set to appear before a Senate appropriations subcommittee to discuss a proposed $18 billion slash to the NIH budget—about 40 percent of the agency's current allocation. The letter, titled the Bethesda Declaration (a reference to the NIH's location in Bethesda, Maryland), is modeled after the Great Barrington Declaration, an open letter published by Bhattacharya and two of his colleagues in October 2020 that criticized 'the prevailing COVID-19 policies' and argued that it was safe—even beneficial—for most people to resume life as normal. The approach that the Great Barrington Declaration laid out was, at the time, widely denounced by public-health experts, including the World Health Organization and then–NIH director Francis Collins, as dangerous and scientifically unsound. The allusion in the NIH letter, officials told me, isn't meant glibly: 'We hoped he might see himself in us as we were putting those concerns forward,' Jenna Norton, a program director at the National Institute of Diabetes and Digestive and Kidney Diseases, and one of the letter's organizers, told me. None of the NIH officials I spoke with for this story could recall another time in their agency's history when staff have spoken out so publicly against a director. But none of them could recall, either, ever seeing the NIH so aggressively jolted away from its core mission. 'It was time enough for us to speak out,' Sarah Kobrin, a branch chief at the National Cancer Institute, who has signed her name to the letter, told me. To preserve American research, government scientists—typically focused on scrutinizing and funding the projects most likely to advance the public's health—are now instead trying to persuade their agency's director to help them win a political fight with the White House. Bhattacharya, the NIH, and the Department of Health and Human Services did not respond immediately to a request for comment. The agency spends most of its nearly $48 billion budget powering science: It is the world's single-largest public funder of biomedical research. But since January, the NIH has canceled thousands of grants —originally awarded on the basis of merit—for political reasons: supporting DEI programming, having ties to universities that the administration has accused of anti-Semitism, sending resources to research initiatives in other countries, advancing scientific fields that Trump officials have deemed wasteful. Prior to 2025, grant cancellations were virtually unheard-of. But one official at the agency, who asked to remain anonymous out of fear of professional repercussions, told me that staff there now spend nearly as much time terminating grants as awarding them. And the few prominent projects that the agency has since been directed to fund appear either to be geared toward confirming the administration's biases on specific health conditions, or to benefit NIH leaders. 'We're just becoming a weapon of the state,' another official, who signed their name anonymously to the letter, told me. 'They're using grants as a lever to punish institutions and academia, and to censor and stifle science.' NIH officials have tried to voice their concerns in other ways. At internal meetings, leaders of the agency's institutes and centers have questioned major grant-making policy shifts. Some prominent officials have resigned. Current and former NIH staffers have been holding weekly vigils in Bethesda, commemorating, in the words of the organizers, ' the lives and knowledge lost through NIH cuts.' (Attendees are encouraged to wear black.) But these efforts have done little to slow the torrent of changes at the agency. Ian Morgan, a postdoctoral fellow at the NIH and one of the letter's signers, told me that the NIH fellows union, which he is part of, has sent Bhattacharya repeated requests to engage in discussion since his first week at the NIH. 'All of those have been ignored,' Morgan said. By formalizing their objections and signing their names to them, officials told me, they hope that Bhattacharya will finally feel compelled to respond. (To add to the public pressure, Jeremy Berg, who led the NIH's National Institute of General Medical Sciences until 2011, is also organizing a public letter of support for the Bethesda Declaration, in partnership with Stand Up for Science, which has organized rallies in support of research.) Scientists elsewhere at HHS, which oversees the NIH, have become unusually public in defying political leadership, too. Last month, after Health Secretary Robert F. Kennedy Jr.—in a bizarre departure from precedent—announced on social media that he was sidestepping his own agency, the CDC, and purging COVID shots from the childhood-immunization schedule, CDC officials chose to retain the vaccines in their recommendations, under the condition of shared decision making with a health-care provider. Many signers of the Bethesda letter are hopeful that Bhattacharya, 'as a scientist, has some of the same values as us,' Benjamin Feldman, a staff scientist at the National Institute of Child Health and Human Development, told me. Perhaps, with his academic credentials and commitment to evidence, he'll be willing to aid in the pushback against the administration's overall attacks on science, and defend the agency's ability to power research. But other officials I spoke with weren't so optimistic. Many at the NIH now feel they work in a 'culture of fear,' Norton said. Since January, NIH officials have told me that they have been screamed at and bullied by HHS personnel pushing for policy changes; some of the NIH leaders who have been most outspoken against leadership have also been forcibly reassigned to irrelevant positions. At one point, Norton said, after she fought for a program focused on researcher diversity, some members of NIH leadership came to her office and cautioned her that they didn't want to see her on the next list of mass firings. (In conversations with me, all of the named officials I spoke with emphasized that they were speaking in their personal capacity, and not for the NIH.) Bhattacharya, who took over only two months ago, hasn't been the Trump appointee driving most of the decisions affecting the NIH—and therefore might not have the power to reverse or overrule them. HHS officials have pressured agency leadership to defy court orders, as I've reported; mass cullings of grants have been overseen by DOGE. And as much as Bhattacharya might welcome dissent, he so far seems unmoved by it. In early May, Berg emailed Bhattacharya to express alarm over the NIH's severe slowdown in grant making, and to remind him of his responsibilities as director to responsibly shepherd the funds Congress had appropriated to the agency. The next morning, according to the exchange shared with me by Berg, Bhattacharya replied saying that, 'contrary to the assertion you make in the letter,' his job was to ensure that the NIH's money would be spent on projects that advance American health, rather than 'on ideological boondoggles and on dangerous research.' And at a recent NIH town hall, Bhattacharya dismissed one staffer's concerns that the Trump administration was purging the identifying variable of gender from scientific research. (Years of evidence back its use.) He echoed, instead, the Trump talking point that 'sex is a very cleanly defined variable,' and argued that gender shouldn't be included as 'a routine question in order to make an ideological point.' The officials I spoke with had few clear plans for what to do if their letter goes unheeded by leadership. Inside the agency, most see few levers left to pull. At the town hall, Bhattacharya also endorsed the highly contentious notion that human research started the pandemic—and noted that NIH-funded science, specifically, might have been to blame. When dozens of staffers stood and left the auditorium in protest, prompting applause that interrupted Bhattacharya, he simply smiled

My 5-year-old survived cancer – twice. Don't put politics before medical research.
My 5-year-old survived cancer – twice. Don't put politics before medical research.

Yahoo

timean hour ago

  • Yahoo

My 5-year-old survived cancer – twice. Don't put politics before medical research.

Few issues in American politics have consistently united both parties like the fight against cancer. While funding levels and strategies may differ, Democrats and Republicans alike recognize that cancer doesn't discriminate – and neither should our commitment to defeat it. Under the Biden administration, the Cancer Moonshot was relaunched to accelerate progress toward a cure. More recently, President Donald Trump announced his 'Stargate' initiative, which aims to harness artificial intelligence in detecting and treating cancer, including through personalized mRNA vaccines. In the United States, cancer is the leading cause of death by disease for children after infancy. Across the political spectrum, there remains a shared hope: that no one should have to endure the pain of losing a loved one or fight this deadly disease. Yet today, that consensus is showing signs of strain. State legislatures across the country are advancing bills to ban or severely restrict the use of – and further research into – breakthrough technologies like mRNA, a technology that is driving promising advancements in cancer. What should be a story of American scientific innovation is being twisted into a political talking point. And it's putting lives at risk. Opinion: Biden's diagnosis shows two things. Cancer hits everyone and some forgot that. If the politicians pushing these bans spent even a few minutes inside a pediatric oncology unit, maybe they'd understand. They'd see floors filled with sick children on small bicycles, pulling IV poles behind them. Children in hospital beds, brave beyond measure. And parents clinging to hope. I've seen it firsthand. I'm a mother whose 5-year-old daughter has survived cancer – twice. My daughter Charlie is one of a small percentage of pediatric cancer patients whose tumors don't show up on standard blood tests. Her cancer went undetected for more than a year. By the time doctors found it, it had already spread to her liver. She was just 3 years old and had Stage 4 cancer. Once Charlie's cancer was detected, we rushed into treatment: high-dose chemotherapy, stem cell transplants and multiple surgeries. After months of treatment, we got the news every parent prays for: Charlie was cancer-free. But just a few months later, scans revealed a relapse. Two small nodules were found on her lung. Her baby brother was only two months old when we learned her cancer had returned. Relapse treatment was grueling. Charlie lost weight and muscle mass. She needed a feeding tube to stay nourished, hydrated and medicated. But through it all, she never lost her smile. Her strength became ours. And while we juggled caring for a newborn and two other children, we held onto hope, because science gave us a reason to. Thanks to expert care at Seattle Children's and research-backed protocols, she's once again cancer-free. She started preschool this year. She's coloring, laughing and chasing her siblings again. Every option we had was made possible by decades of public investment in research. Families who came before us joined clinical trials. Lawmakers chose to fund pediatric science and cancer research. That is the same kind of work mRNA research builds on today. Opinion alerts: Get columns from your favorite columnists + expert analysis on top issues, delivered straight to your device through the USA TODAY app. Don't have the app? Download it for free from your app store. Researchers are developing an mRNA-based diagnostic test that could catch cancers like hers earlier, when they're more treatable. The test uses mRNA from her original tumor to detect any circulating cancer cells through a simple blood draw. Catching a relapse early could be lifesaving. We first learned about this test in 2023, and knowing it's almost within reach brings us, and families like ours, so much hope. Beyond mRNA-based diagnostic tests, mRNA has also shown early promise as a therapy for cancer patients, enabling personalized treatment that could more effectively target one's tumor. That kind of innovation is exactly what's under threat right now. The role of mRNA technology in oncology has been studied for decades, and yet some lawmakers want to roll this progress back, arguing it is untested and unsafe. This technology, along with many innovations that come from federally supported medical research, is a critical source of hope for families around the world. I'm a doctor. So is my mother. When she got cancer, I realized how little that mattered. | Opinion When you're watching your child battle cancer, every advancement matters. I know firsthand how critical it is to catch cancer early and have access to every possible treatment option. When politicians politicize science – when they ban or restrict it based on misinformation and politics – they aren't protecting families like mine. They're limiting our options. They're slowing down the breakthroughs that could save lives. We can't afford to let misinformation and polarized politics dictate the future of lifesaving research. Thanks to innovation in medical research, Charlie is thriving today, but far too many kids are still fighting. Let's ensure science continues to move forward for all of our children. Emily Stenson is a childhood cancer advocate and the mother of 5-year-old two-time cancer survivor Charlie Stenson. She lives in Seattle. You can read diverse opinions from our USA TODAY columnists and other writers on the Opinion front page, on X, formerly Twitter, @usatodayopinion and in our Opinion newsletter. This article originally appeared on USA TODAY: Cancer research saved my child's life. Fund mRNA innovation | Opinion

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store